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Abstract
Background: Clostridium perfringens (Cp) is a Gram-positive anaerobic bacterium that causes necrotic
enteritis (NE) in poultry when it overgrows in the small intestine. NE disease has previously been
controlled through the use of growth-promoting antibiotics. This practice was recently banned in
European countries, leading to significantly increased incidence of NE threatening the poultry industry.
Control strategies and technology as substitutes to dietary antibiotics are therefore urgently required. To
develop the substitutes, it is important to understand host immune responses to Cp infection. However,
the knowledge is still lacking. We therefore investigated gene expression profiles within immunologically-
relevant tissue, the spleen, in order to identify factors that are involved in immunity to NE and have
potential as therapeutic targets.
Results: Use of a 44 K Agilent chicken genome microarray revealed significant up-regulation of many
immune-associated genes in Cp-challenged chickens, including galectin 3, IFNAR1, IgY-receptor, TCRγ,
granzyme A, and mannose-6-P-R, which were subsequently validated by quantitative PCR assays. Functional
annotation of differentially expressed genes was conducted using the High Throughput Gene Ontology
Functional Annotation database. Medicated and Non-medicated chickens had similar annotation profiles
with cell activities and regulation being the most dominant biological processes following Cp infection.
Conclusion: Broiler chickens demonstrated an intricate and holistic magnitude of host response to Cp
challenge and the development of NE. Although the influence of dietary antibiotics appeared to be less
significant than the disease process, both had a considerable impact on the host response. Markers
previously identified in intestinal inflammatory diseases of other species, including humans, and indicators
of enhanced antibody responses, appeared to be involved in the chicken response to Cp challenge. The
significance in host immune responses of immune mediators identified from the present study warrants
further studies to verify their functions during NE development and to determine their potential
application to control NE disease.
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Clostridium perfringens (Cp) is an environmentally domi-
nant anaerobic bacterium, which upon ingestion and
overgrowth, can cause intestinal inflammation and
necrotic tissue damage, wherein the collective disease
pathology is termed necrotic enteritis (NE). The bacte-
rium is Gram-positive, producing spores and a variety of
toxins. Cp strains are further classified into subtypes A-E
based on the type of toxin they produce (a, b, o and i) and
the degree of NE that is resulted, although additional tox-
ins, such as beta2 toxin (cpb2), enterotoxin (cpe), and
necrotic enteritis toxin B-like toxin (netB), were recently
discovered [1-3]. Sub-clinical NE in poultry is caused by
Cp type A and occasionally by type C. Alpha (α)-toxin
production has been considered to be to be a major viru-
lence determinant associated with NE disease [4-6]. This
was recently challenged by a study of an α-toxin mutant
that retained full virulence in a chicken NE model [7].
NetB toxin was also shown to be critical for the produc-
tion of NE, although not all NE isolates were found to
possess the netB gene [3]. Although primarily thought to
be involved in virulence in humans and piglets, beta (β)-
toxin has been suggested to not have great impact on the
outcome of NE in chickens, based on the expression of the
toxin gene in healthy challenged chickens [8]. Sub-clinical
Cp infection in chickens and turkeys also manifests as
macroscopic lesions in the small intestine, as well as the
caeca, liver, bursa of Fabricius, and kidney [9]. Although
sub-clinical Cp infection is commonly observed and only
leads to decreased growth performance and mild focal
necrosis of the intestinal mucosa of chickens, NE is quite
discernably a disease with systemic impact and can lead to
acute mortality rates reaching 50% [10]. The severity of
NE outbreaks is realized in reports of Cp prevalence in the
intestinal tract of poultry ranging from 75% to 95%, with
up to 84% of processed poultry meat being Cp positive
[11].
Infection with Cp is not the sole factor for the develop-
ment of NE disease. Predisposing factors such as intestinal
damage caused by coccidial pathogens, dietary proteins,
and dietary carbohydrate proportions and properties have
also been shown to strongly influence the incidence of NE
in broilers [12,13]. Since the induction of NE is described
as multi-faceted, broad-spectrum growth-promoting anti-
biotics have primarily been implemented to control the
incidence of the inflammatory disease in poultry to date.
The recent ban on the use of growth-promoting antibiot-
ics in European food animal production has led to more
prevalent Cp infection in poultry and increased outbreaks
of NE, threatening the poultry industry [14]. As such,
development of strategies to control NE disease has
become urgent for both the industry and research com-
munities. Different approaches can be taken for control-
ling Cp infection, including improving the management
of production systems, such as controlled diets and envi-
ronmental factors, targeting Cp through the control of cell
proliferation or toxin production, and enhancing chicken
immune defence systems. However, to date, no single "sil-
ver bullet" has been invented to control the disease in the
field as efficiently and cost-effectively as the prophylactic
use of antibiotics. Due to the incompletely characterized
profile of Cp-related immune mechanisms, a progressive
approach to pursuing prophylactic measures would be to
compare the immune response in previously well-charac-
terized antibiotic-medicated chickens, to that of birds that
have not been medicated, so that the difference in protec-
tive mechanisms may be identified.
Controlling NE disease through probiotic bacteria has
been tested previously. Colonization of Cp in the chicken
intestine was suppressed when chickens were adminis-
tered Bacillus subtilis prior to Cp challenge [15]. Similarly,
a commercial Lactobacillus-based probiotic product (All-
Lac XCL) was reported to reduce NE-associated mortality
from 60% to 30%, but not the degree of NE lesions [16].
Vaccination could be another means to prevent NE in
poultry. Previous studies have demonstrated that other
animal species including mice, piglets, and calves showed
a reduction in the disease prevalence after vaccination
with Clostridium toxins [17-19]. Protection against sub-
clinical NE was also reported in broilers when the chick-
ens were vaccinated with Cp type A and type C toxoids
[20]. More recently, virulent and avirulent Cp strains and
respective secreted proteins were tested for their ability to
orally immunize chickens [6,21]. Virulent Cp isolates pro-
tected chickens from subsequent virulent challenge,
whereas the avirulent isolate did not [21]. As indicated by
serum and intestinal antibody responses, Cp proteins sig-
nificantly protected broiler chickens against mild Cp
infection, whereas only a limited number of proteins
offered protection against more severe challenge [6]. Fur-
ther studies are required to identify true antigens that are
able to fully protect chickens from Cp infection.
Gut-associated pathogens have been shown to induce
cytokine gene expression changes during systemic infec-
tion in chickens, prevalent during various aspects of
pathogenesis and immune response, including cellular or
tissue entry, immune cell recruitment and pathogen clear-
ance [22]. For example, infection with different Salmonella
species, has been repeatedly shown to regulate both
chemokine and cytokine expression across infection time
points [22,23]. Similarly, chicken immune cell cultures
infected with various Eimeria species have shown a wide
array of cytokine responses in cells derived from geneti-
cally-defined lines of chickens, demonstrating the influ-
ence of host genetic background on susceptibility to
disease [24,25]. In many cases, these types of studies are
correlated with quantification of pathogen load andPage 2 of 13
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lesions. In the case of Cp infection, our group has previ-
ously described bacterial quantification and toxin gene
expression in relationship to NE lesion score [26]. How-
ever, in comparison to other gut-associated pathogens
described above, there is little knowledge about the
chicken immune response to Cp infection. The limited
reports include recombinant chicken IL-18 used as an
adjuvant to stimulate antibody-mediated immune
response to chicken pathogens, including Cp α-toxoid
[27]. Recently, Collier et al. [28] reported an increase in
gene expression of ileal IL-4, IL-10 and IFN-γ in Cp
infected chickens when compared with uninfected birds,
which coincided with increased intestinal NE lesions and
mortality after 2–4 days post-challenge. In addition, Park
et al. [29] investigated the immune response of chickens
co-infected with Eimeria maxima (EM) and Cp by examin-
ing the gene expression of a limited number of cytokines
and chemokines with quantitative PCR assays. The intes-
tinal expression of a panel of cytokine and chemokine
genes following EM/Cp co-infection showed repression of
pro-inflammatory interleukin genes (e.g. IL-12, IL-17)
and up-regulation of IL-8 and IL-10 compared with single
infection of Cp or EM. Although expression of many
cytokine genes seemed to be strongly induced or repressed
in Cp-only treated chickens compared with uninfected
birds, no statistical analyses of direct comparisons were
presented [29].
The recent development of chicken DNA microarrays,
including both cDNA [30] and oligo arrays [31], offered
us an opportunity to investigate global gene expression
profiling of host response to Cp infection. By using the
low-density chicken immune cDNA array [30], we first
examined the gene expression profiles in the spleen of
broilers experimentally infected with C. perfringens and
found that a more than one immune response pathway
was targeted in the host response to Cp infection, includ-
ing the differential expression of genes within the MHC
class I and II and apoptosis pathways [32]. Since oligo
arrays are generally of better specificity, sensitivity, and
reproducibility than cDNA arrays [33], we revisited the
same spleen samples with the 60-mer 44 K chicken whole
genome custom array manufactured using the Agilent
Technology [31] for a more comprehensive study of the
host response to Cp infection. The chickens used for these
microarray analyses were from the same infection experi-
ment that investigated the relationships of cell prolifera-
tion and α-toxin gene expression of Cp in the chicken
intestine with the development of NE lesions [26].
Although Cp infection and NE lesions occurred in the
small intestine of chickens, C. perfringens has been
detected in the spleen of infected chickens [28]. Our pre-
liminary data also support this observation (unpublished
data). Given this fact and that we were interested in both
the local response in the intestine and systemic immune
response for defining protective mechanisms against NE,
we chose the spleen as our first effort to study the host
response to Cp infection. In addition, in mice, intestinal
commensal bacteria have been shown to be contained
within the gut-associated lymphoid tissues whereas, bac-
terial pathogens have been shown to break the barrier sug-
gested to be created by the mesenteric lymph nodes
(MLN) and are thus found in other lymphoid organs [34].
Considering that Cp can be present in the gastrointestinal
(GI)-tract of chickens without causing NE disease, the dif-
ference between birds that succumb to disease and those
that may harbour the bacteria, could be due to a similar
mechanism in chickens whereby once the pathogen
reaches systemic lymphoid organs, the host response and
disease outcome maybe drastically different than when
contained within the GI-tract. Therefore, in the present
study, we have analyzed a whole-genome expression pro-
file within the spleen of Cp-infected chickens compared
with uninfected birds within the context of antibiotic
treatments at a series of time points following the infec-
tion.
Methods
Bacterium
A Type A strain of C. perfringens was grown in Mueller-
Hinton broth or on Mueller-Hinton agar containing 5%
(vol/vol) sheep blood at 37°C within an anaerobic
atmosphere (85% N2, 10% CO2, and 5% H2).
Experimental animals
The chickens used in the present study were the same
birds for previous publications studying gene expression
of α-toxin in the chicken intestine [26] and host response
to Cp infection with a low-density chicken immune cDNA
array [32]. Broiler chickens (Ross × Ross) were reared
under the guidelines of the Canadian Council on Animal
Care. Six-hundred one-day-old chicks were equally
divided among 12 pens (50 birds/pen). Each pen was
assigned to one of two dietary treatments: (i) a typical all-
vegetable starter diet (Shur-Gain; Nutreco Agresearch
Canada) containing zinc bacitracin (55 mg/kg) or (ii) the
same diet without bacitracin. The first day of the trial was
designated day 0 post-hatch. On day 18, birds were chal-
lenged for 16 h with C. perfringens (107 CFU/g feed, 40 g
feed/chicken) through the diet after 8 h of starvation.
Twelve birds (2 birds per pen) randomly selected from
each group were euthanized before and after clostridial
challenge daily for five days, which were designated days
0, 1, 2, 3, and 4 post-challenge (D0, D1, D2, D3, and D4Page 3 of 13
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each group for total RNA isolation. RNA samples from
D0, D1, D2, and D4 PI birds were used to compare anti-
biotic-medicated to non-medicated chickens at each time
point using microarray analyses.
RNA extraction
Spleen tissue was homogenized using a Tissue Miser
(Fisher Scientific, Houston, TX). Total RNA was isolated
from each homogenized tissue using Trizol extraction
method as described by the manufacturer (Invitrogen,
Carlsbad, CA). DNA was removed from the samples using
TURBO DNA free™ Kit (Ambion, Austin, TX) according to
the manufacturer's protocol. The RNA quantity and purity
were determined by NanoDrop ND-1000 spectropho-
tometer at 260/280 nm (Nano Drop Technologies, Wilm-
ington, Delaware). The integrity of total RNA was assessed
with an Agilent Bioanalyzer 2100 and RNA 6000 Nano
LabChip Kit (Agilent Technologies, Palo Alto, CA). The
RNA Integrity Numbers (RINs) for the samples were
obtained. Only RNA samples with RIN values of 6, or
higher, were used for further analysis.
cDNA and cRNA preparation
The cDNA for quantitative PCR analysis was synthesized
from 1 μg purified RNA using random hexamers and the
Superscript II First Strand cDNA Synthesis kit (Invitrogen,
Burlington, Ontario). cRNA for microarray hybridization
was prepared as described previously [31]. Briefly, a 500
ng of aliquot of total RNA was reverse transcribed into
cDNA using the Low RNA Input Fluorescent Linear
Amplification Kit (Agilent Technologies, Palo Alto, CA).
Synthesized cDNA was transcribed into cRNA and
labelled with either cyanine 3 or cyanine 5-labelled nucle-
otide (Perkin Elmer, Wellesley, MA). Labelled cRNA was
purified with RNeasy Mini columns (Qiagen, Valecia,
CA). The quality of each cRNA sample was verified by
total yield and specificity calculated based on NanoDrop
ND-1000 spectrophotometer measurement (NanoDrop
Technologies).
Microarray experiment design
The design for the present study is similar to our recent
report with the low-density chicken immune array [32],
except that the 44 K Agilent chicken genome oligo micro-
array was used. The microarray has been submitted to the
National Center for Biotechnology Information Gene
Expression Omnibus database under the following acces-
sion number: GPL4993. To account for any bias inherent
to the fluorescent dyes, a dye swap was performed such
that within each treatment group (e.g. Medicated) half of
the replicates were labelled with Cy3 and the other half
were labelled with Cy5 at each time point. There were six
hybridizations performed between Medicated and Non-
medicated replicates at D0, D1, D2, and D4 PI, wherein
two birds from each pen were pooled within each group.
Microarray hybridization and analysis
Microarray hybridizations were carried out on labelled
cRNAs with specificity greater than 8 using the in situ
Hybridization Kit Plus (Agilent Technologies). Arrays
were incubated at 65°C for 17 h in Agilent's microarray
hybridization chambers and subsequently washed accord-
ing to the Agilent protocol. Arrays were scanned at 5 μm
resolution using GenePix Personal 4100A (Molecular
Devices Corporation, Sunnyvale, CA). Auto Photomulti-
plier tube (PMT) gains were adjusted to obtain a ratio of
Cy3 and Cy5 channels intensities between 0.95 and 1.05.
The signal intensity of all features on each image was
quantified by Genepix pro 6.0 software (Molecular
Devices Corporation, Downingtown, PA) for further anal-
ysis.
The signal intensity of each expressed gene was globally
normalized (LOWESS) [35] using the R statistics program
and presented on a natural log scale. Microarray data was
submitted as GEO series GSE14684 and GSE14759 to
Gene Expression Omnibus. A mixed model that included
the fixed effects of dye (Cy3 and Cy5), treatment, time,
array, and all interactions among treatment and time was
used to identify differentially expressed genes between
treatments, at the 0.1% significance level using SAS (SAS
Institute, Cary, NC). Microarray hybridizations were used
to compare Medicated to Non-medicated chickens at each
time point (e.g. Medicated vs. Non-medicated on D0 PI)
and between time points within treatments (e.g. D0 PI vs.
D1 PI in Medicated birds). P value and fold changes
between each comparison for each gene were calculated.
False discovery rate (FDR) (q values) was calculated by R
program according to Benjamini and Hochberg's method
[36].
Functional annotation of the biological processes involv-
ing significantly differentially expressed genes was carried
out using an unreleased version of the High Throughput
Gene Ontology Functional Annotation Toolkit (HTGO-
FAT, http://liru.ars.usda.gov/mainbioinformatics.html).
This program was utilized to assign updated Gene Ontol-
ogy numbers [37], Enzyme Commission numbers [38],
and mappings to Kyoto Encylopedia of Genes and
Genomes (KEGG) Pathways [39]. Statistics related to
over-representation of functional categories were per-
formed using a Fisher Exact statistic methodology [40]. In
brief, differentially expressed genes (p < 0.001) were
selected and separated based on direction of expression
(i.e. up- or down-regulated). Data mining to PubMed IDsPage 4 of 13
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ditions or terms (e.g. chicken and Clostridium) that co-
occur with gene names and symbols that are represented
in each dataset. Subsequent mapping and clustering was
carried out using the Database for Annotation, Visualiza-
tion and Integrated Discovery (DAVID) [41].
Quantitative PCR
The quantitative PCR was performed on a Stratagene
MX3005 thermal cycler with brilliant SYBR green Q-PCR
Master Mix (Stratagene, La Jolla, CA). cDNA was diluted
10-fold, and 1 μl of each diluted sample was added to a
25-μl reaction, also containing 12.5 μL of 2× master mix,
150 nM of each primer, and 30 nM ROX reference dye.
Cycling parameters were as follows: 10 min at 95°C, then
40 cycles of 95°C for 30 s, annealing temperature for 30
s, and 72°C for 30 s, and extension for 2 min at 72°C.
Gene-specific annealing temperatures are outlined in
Table 1. Standard curves were generated by amplifying 3
technical replicates of a serial dilution of plasmid DNA.
One plasmid from the serial dilution was used as the PCR
calibrator when running biological replicates. The PCR
amplification efficiency (E) was calculated using the slope
of the standard curve, E = 10(-1/slope). Statistical signifi-
cance was determined by unpaired T test using mean and
SEM of the biological replicates within treatment groups
(p < 0.05).
Results
Microarray analyses
Effect of bacitracin on the expression of genes
The gene expression data were compared in order to iden-
tify the differentially expressed genes between Medicated
and Non-medicated groups of chickens at each time point
before and after clostridial challenge, including D0, D1,
D2, and D4 PI. Few changes were observed at each time
point, however the greatest divergence between antibi-
otic-Medicated and Non-medicated treatment groups
occurred on D4 PI for all array results, where D4 PI
showed 118 differentially expressed genes with significant
changes (p < 0.001) (Figure 1). The remaining time points
showed less than half the number of genes with signifi-
cant changes, in which D0 PI (pre-challenged baseline),
D1 PI and D2 PI had 9–39 differentially expressed genes
between treatment groups (Figure 1). The proportion of
genes that were expressed more in Medicated birds than
Non-medicated birds was different at each time point. On
D0 PI, Medicated group had higher expression of 28% of
differentially expressed genes than Non-medicated birds.
On D1 PI, all of the genes showed higher expression in the
Medicated group compared to the Non-medicated group.
On D2 PI, equal numbers of the differentially expressed
genes showed higher expression in the Medicated groups
and Non-medicated groups. Similarly, on D4 PI 43% of
the differentially expressed genes showed higher expres-
sion in the Medicated group than the Non-medicated
group. Of all the genes differentially expressed with signif-
icant changes between Medicated and Non-medicated
groups, immune-mediating genes were rarely identified
and no genes were commonly expressed at all time points
when comparing differentially expressed genes on D0,
D1, D2 and D4 PI.
Temporal genes expression changes
There were 8,000 to 11,000 genes differentially expressed
in the birds before and after clostridial challenge, regard-
less of different time points and the treatment of baci-
tracin (Figure 2A). Within each time point, the majority of
genes were significantly expressed in both the Medicated
and Non-medicated groups (black bars). Less genes, yet
seemingly similar numbers (941–1348) were significantly
expressed and unique to either the Medicated (hatched
bars) or Non-medicated groups (open bars) (Figure 2A).
A comparison of post-challenge time points showed that
there was a much greater difference in the number of dif-
ferentially expressed genes between D1, D2, and D4 PI
(Figure 2B). The number of genes in common for Medi-
cated and Non-medicated groups (black bars) was 12–36
genes, representing a much smaller proportion than in the
pre- vs. post-challenge comparison. In the comparison of
post-challenged birds, genes unique to Medicated
(hatched bars) and Non-medicated (open bars) birds
dominated the host response with the Medicated group
showing a larger significant expression profile during D1
Table 1: Primer sequence, annealing temperature [AT] (degrees Celsius – °C) and fragment length [FL] (base pairs – bp) for genes 
amplified using Q- PCR.
Gene Name Forward Primer Reverse Primer AT (°C) FL (bp)
Galectin 3 CTGGATACCCAGGTGCCTAT AGTACGGTGCAGTTGGTCCT 55 180
IFNAR1 CTTTGGGATCCTCGTTCTGA GCAACACAGGAGGCTTTCAT 55 201
Mannose-6-P-R AAGCTAATGAGAATGAAACGGAGTG CATCTGGGATGGTTAACACTTCATC 60 180
MCG24 TCTGTACAAATTCTGCAGGTCGAAA AGAGATTCACATTACCTCTTGCCAA 55 222
TCRγ CACATGACACACAAGGCAGCA TAGCACAGAGAGCAGGAGAGCTTAT 55 225
Granzyme A TGGGTGTTAACAGCTGCTCATTGC GGGGAATGACTTTCACAGCGCTA 52 213
IgY R AGGAGAACCCGGCCACAC ATCTGACCACTGCCAGCCA 60 180Page 5 of 13
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cated group. The pattern was reversed when a comparison
was made between D2 and D4 PI.
Categorical annotation of differentially expressed genes
Annotation of all significant genes was carried out based
on gene sequence association with known biological
processes, including those associated with metabolics of
chicken RNA, DNA, protein and cell activity and regula-
tion, and some that were not able to be specifically classi-
fied. These categories were chosen based on frequency
within the dataset after summarizing the full annotation
profile, as described in Additional file 1. Medicated and
Non-medicated groups had near identical annotation
profiles, where cell activity and regulation were the most
dominant biological processes during the time course of
Cp infection (Figure 3). The differentially expressed genes
that were not in common between Medicated and Non-
medicated groups over the time course of infection were
fairly dispersed in a homogenous manner, with the
number of annotated genes ranging from 28.7–32.5% of
total number of genes displaying significant expression.
The number of immune-specific annotated genes was a
much smaller proportion of the total number of signifi-
cant genes (1.74–2.18%) (Table 2). Of the differentially
expressed immune-specific genes, we chose a small
number to be investigated for treatment and temporal
expression patterns as well as for technical validation by
quantitative PCR.
Relevant genes regulated during CP infection
Expression patterns were observed from functionally-rele-
vant chicken genes in both microarray analysis and quan-
titative PCR validation. Specifically, genes involved in
inflammation, antibody response, antigen recognition,
apoptosis, and immune-associated metabolic processes
showed significant regulation after clostridial challenge.
Figure 4 displays the results of microarray analysis of
some potential target genes. In general, the expression of
all the listed genes was up-regulated in response to
clostridial challenge, regardless of the treatment with baci-
tracin. IL-18, IgY Receptor, granzyme A, TCR-γ, GlcNAc, and
galectin 3 had higher expression in Medicated birds than
Non-medicated groups at all time points, when normal-
ised to pre-challenged birds. Exceptions of this observa-
tion occurred only in the comparison of D4 to D0 PI with
IFNAR1 and mannose-6-phosphate receptor (mannose-6-P-
R). Among different temporal patterns, the up-regulation
of GlcNAc and galectin 3 expression increased during post-
challenge days, while granzyme A, IgY Receptor, and IL-18
demonstrated less up-regulation post-challenge. IFNAR1,
mannose-6-P-R, and TCR-γ showed either increased or
decreased up-regulation among different post-challenge
days. The up-regulation of most genes after clostridial
challenge exceeded 3-fold changes. TCR-γ had the highest
changes (near 14-fold), while galectin 3 exhibited the low-
est (more than 2-fold). Although some expression pat-
terns were similar, these could not be attributed to one of
the above- mentioned immune function over the others.
Quantitative PCR verification
Based on the microarray results, genes with a previously
defined function and reported correlation to intestinal
inflammation or Cp pathology were selected for valida-
tion by quantitative PCR. These included the genes encod-
ing Galectin 3, IFNAR1, IgY-R, TCRγ, granzyme A, MCG-
24, and Mannose-6-P-R, which were differentially
expressed on D1, D2 and D4 PI, when compared with the
birds before the challenge (D0 PI). By comparison to β-
actin (internal control), the expression level of selected
genes was determined. In parallel to the microarray anal-
yses, quantitative PCR expression ratios were established
by comparing normalised relative expression at each time
point after clostridial challenge to that before the chal-
lenge (D0 PI) within each treatment group. Up to six com-
parisons were conducted for each of the genes.
Quantitative PCR assays were able to reproduce 60–100%
of expression patterns of each gene examined that had
been revealed by the microarray analyses (Table 3).
Numbers of differentially expressed genes between Medi-cated and Non-medic ted group  of birds at each examined tim  pointFigur  1
Numbers of differentially expressed genes between 
Medicated and Non-medicated groups of birds at 
each examined time point. Medicated and Non-medi-
cated groups of chickens represent the birds on diets con-
taining bacitracin (55 ppm) or no antibiotics. Expression data 
were calculated by mixed model analysis of mean signal 
intensity minus median background intensity acquired from 
the Agilent 44 K chicken microarray (p < 0.001).
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Recently, we reported the use of a low-density cDNA
chicken immune-specific microarray to investigate the
host immune response to Cp infection by examining gene
expression profiles in spleens from experimentally
infected chickens [32]. Our results indicated that a more
than one immune response pathway was targeted, includ-
ing the differential expression of genes within the MHC
class I and II and apoptosis pathways. Very recently, a 44
K chicken whole genome custom oligo array was devel-
oped, which was manufactured with the Agilent Technol-
ogy [31]. This allowed us to expand our research by
compensating for the size limitation of the previous array
and thus to more robustly investigate the host response to
Cp infection. Importantly, the genes that were previously
identified by our group as functionally relevant in the
spleen of Cp-challenged chickens (e.g. MHC class I and II
family members) were also shown to be differentially
expressed using the large-scale array, confirming the tech-
nical integrity of both experiments and the biological
importance of the gene families.
Upon obtaining the large set of statistically significant
gene expression data derived from the analysis of the 44 K
microarray, further and extensive data mining and anno-
tation were required to interpret and correlate the results.
Numerous reports of expression data annotation have
been previously described, in order to assess the large data
sets that are considered to be the fruition of high-through-
put methodologies. Annotation is necessary because typi-
cal methods used to filter the data to a manageable load,
such as clustering, can further complicate the dataset, as
opposed to converge the output. The Gene Ontology Con-
sortium is a collection of databases for a variety of organ-
isms, which is commonly used to annotate gene
expression based on existing knowledge of biological
function and a limited functionally-derived vocabulary.
This method is organised in a hierarchy of key words
including molecular function, biological process, and cel-
lular component [42]. Biological function can then be
applied to relevant pathways, through databases such as
KEGG (Kyoto Encyclopedia of Genes and Genomes).
However, these databases are not nearly as well-developed
Numbers of differentially expressed genes in temporal comparison of Medicated and Non-medicated groups of chickensFigur  2
Numbers of differentially expressed genes in temporal comparison of Medicated and Non-medicated groups of 
chickens. (A) Comparison of post- and pre-challenges. Number of differentially expressed genes between pre – and post-
challenge time points. (B) Comparison of post-challenge on different days. Number of genes unique to Medicated (hatched 
bars), unique to Non-medicated (open bars) treatment groups and number of genes in common for both Medicated and Non-
medicated groups (black bars) are represented. Expression data were determined by mixed model analysis of mean signal 
intensity minus median background intensity measured from Agilent 44 K chicken microarray (p < 0.001). Medicated and Non-
medicated groups of chickens represent the birds on diets containing bacitracin (55 ppm) or no antibiotics.
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Table 2: Numbers of genes with known functions differentially expressed before and after clostridial challenge within Medicated and 
Non-medicated treatment groups of chickens.
Number of Genes per Treatment Group
Post-/pre-challenge % of Total Medicated Non-medicated
D1/D0 PI Total Number of Genes 2205
Number of Annotated as General Function 633 28.7 310 323
Number of Annotated as Immune Function 48 2.18 26 22
D2/D0 PI Total Number of Genes 2351
Number of Annotated as General Function 763 32.5 472 291
Number of Annotated as Immune Function 41 1.74 29 12
D4/D0 PI Total Number of Genes 2679
Number of Annotated as General Function 819 30.6 461 358
Number of Annotated as Immune Function 48 1.79 26 22
Comparison of proportions of functional categories within treatment groups resulting from GO AnnotationFigure 3
Comparison of proportions of functional categories within treatment groups resulting from GO Annotation. 
Number of functional categories within biological processes defined by Go Annotation using an unreleased version of the High 
Throughput Gene Ontology Functional Annotation Toolkit (HTGOFAT, http://liru.ars.usda.gov/mainbioinformatics.html) 
applied to differentially expressed genes (p < 0.001) in Medicated and Non-medicated birds for all time points combined.
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BMC Genomics 2009, 10:260 http://www.biomedcentral.com/1471-2164/10/260as the previously mentioned GO databases, suggesting
that gaps in the annotation process exist [42]. Further-
more, when studying species that have less known gene
functionality (e.g. the chicken) compared with the more
widely-studied human and mouse, the annotation proc-
ess can be more challenging. Nonetheless, as shown by
the present study (Figure 3 and Additional file 1), GO
annotation did provide a multitude of biological proc-
esses potentially involved in the chicken response to Cp
infection and NE development, and identified fewer proc-
esses that are solely affected by feeding the birds a Medi-
cated diet (bacitracin) compared to the Non-medicated.
One might note that this process did not narrow the
results to a manageable size. On the contrary, the GO
annotation established a data categorization that leads to
a new realm of questions regarding the roles of these proc-
esses in Cp infection. Moreover, the results of GO annota-
tion required a user-imposed, arbitrary clustering of the
processes into more general terms, as demonstrated in
Figure 3.
Specific target genes were selected from the list of genes
that were differentially expressed to a significant degree
for further studies to infer biological function. Selection
was based on GO annotation and previous reports of dis-
ease pathology associated with NE in chickens or other
species, and other diseases that manifest similarly. Specif-
ically, NE lesions have been observed in the small intes-
tine, caeca, liver and kidney of both chickens and turkeys
[9], and the small intestine is the main site and character-
ized by thin friable walls indicative of exacerbated inflam-
mation [43-45]. Histopathological studies in NE diseased
birds have revealed sloughed intestinal epithelium, heter-
ophil infiltration into the lamina propria and enterocyte
necrosis as indicated by the presence of matrix metallo-
proteinase (MMP)-2 enzyme [46,47]. In humans, perivas-
cular infiltration with polymorphonuclear, mononuclear,
and eosinophil cells, in the presence of intestinal necrosis,
is observed in cases of necrotizing enteritis [48]. The
occurrence of eosinophilia, manifesting as a local type I
hypersensitivity response, suggests that this mechanism
may also be present in the chicken during the course of NE
lesion development. Interestingly, our results from the
present study concur with both controlled and excessive
inflammatory processes, as well as an antibody receptor
gene up-regulation potentially related to an eosinophil
Temporal expression acquired by comparing post- to pre-challenged chickens in Medicated and Non-medicated groupsFigure 4
Temporal expression acquired by comparing post- to pre-challenged chickens in Medicated and Non-medi-
cated groups. Microarray expression data represented as fold changes by comparing each time point (D1 PI [D1], D2 PI 
[D2], D4 PI [D4]) in a ratio to D0 PI (D0), indicated for both Medicated (open squares) and Non-medicated (shaded squares) 
treatment groups. Expression data were determined by mixed model analysis of mean signal intensity minus median back-
ground intensity acquired from the Agilent 44 K chicken microarray (p < 0.001).
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BMC Genomics 2009, 10:260 http://www.biomedcentral.com/1471-2164/10/260response. Regardless of the comparison made between
Medicated and Non-medicated chickens, with the aim of
deciphering protective and compromised immune
responses during the course of NE development, the larg-
est difference in expression profiles were observed before
and after clostridial infection irrespective of antibiotic
treatments. Thus during the process of correlating biolog-
ical significance with gene expression data, the focus was
shifted primarily to CP-infected birds in comparison to
non-infected birds.
Of the genes identified as biologically-relevant from func-
tional annotation, galectin 3, IFNAR1, IgY R and TCR-γ
appear to be significantly relevant to the mechanism of
development of NE. Expression profiles of IgY R and TCR-
γ can be speculated to be correlated with innate immunity
responses and eosinophil-regulated inflammation,
respectively, whereas galectin 3 and IFNAR1 biological
functions throughout CP infection are primarily based on
previous characterization of inflammatory disease proc-
esses. Type I interferons (IFNs) are typically described as
important mediators of the anti-viral cytokine response
and more generally speaking, mediators for a pro-inflam-
matory response [49]. For example, type I IFNs are pro-
duced upon bacterial activation of macrophages, which
initiates an up-regulatory autocrine-type production of
IFNs. Specifically, IFN-α and IFN-β, whose expression pat-
terns are mediated by availability of receptors IFNAR1 and
IFNAR2, induce IFN-γ and IL-18 production [50]. In con-
cert, our results indicate up-regulated IFNAR1 expression
in Medicated birds on (D1 and D2 PI) compared to D0 PI
baseline and the same time point ratios in the Non-med-
icated groups. At the latest time point, the expression ratio
is reversed, in which Non-medicated chickens had the
highest level of expression on D4 PI compared to pre-
challenged chickens and compared to the same ratio in
the Medicated group of chickens. This increase in inflam-
mation at early time points in Medicated birds may sug-
Table 3: Validation of microarray results with quantitative PCR assays.
Gene Name Post-/pre-
challenge
Direction of Fold Change in Expression Data Validation Success
Medicated Non-medicated
D1/D0 + +
Granzyme A D2/D0 + + 6/6 (100%)
D4/D0 + +
D1/D0 + +
IFNAR1 D2/D0 + + 5/6 (83%)
D4/D0 + *
D1/D0 + N/A
Galectin 3 D2/D0 + + 3/5 (60%)
D4/D0 * *
D1/D0 + N/A
Mannose 6-P-R D2/D0 + + 4/5 (80%)
D4/D0 + *
D1/D0 + +
TCRγ D2/D0 + N/A 5/5 (100%)
D4/D0 + +
D1/D0 + +
MCG24 D2/D0 N/A N/A 2/3 (66.7%)
D4/D0 N/A *
D1/D0 + +
IgY R D2/D0 + + 5/6 (83%)
D4/D0 * +
N/A: No significant difference between time points was determined from microarray analysis and no quantitative PCR validation was therefore 
performed.
*Direction of fold change was conflicting between microarray and quantitative PCR results.Page 10 of 13
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BMC Genomics 2009, 10:260 http://www.biomedcentral.com/1471-2164/10/260gest a correlation between the protective antibacterial
effect of IFNAR1 on D1 PI and D2 PI. However, the rise in
IFNAR1 expression on D4 PI in Non-medicated birds may
suggest a shift from a protective immune response to an
exacerbated, lesion-forming inflammation as observed in
Cp-infected chickens developing NE. Importantly, IL-18
expression was also up-regulated in clostridial challenged
chickens on D1-D4 PI compared with pre-challenged con-
trols for both the Medicated and Non-medicated groups,
with the Medicated group showing the highest level of
expression of all.
Galectin 3 is a β-galactoside-specific lectin that is
expressed on intestinal epithelial cells (IELs) [51]. Aside
from facilitating adhesion, galectin 3 is strongly involved
in inflammatory processes and mRNA expression has
been observed in IELs from patients with Crohn's disease
and bowel information, colon carcinoma and colitis [51].
Suggesting a connection to the antibody-mediated
response, serum from Crohn's disease patients was shown
to contain anti-galectin-3 IgG antibodies. Moreover,
galectin 3 acts as receptor for IgE, facilitating the up-regu-
lation of IgE production in atopic patients [52]. Specifi-
cally, B cells expressing surface IgE expressed higher levels
of galectin 3 than B cells of other phenotypes [53]. The
relationship between IgE, galectin 3 and eosinophil activ-
ity in allergy-induced inflammation is such that eosi-
nophils, which are activated upon IgE production, are
recruited to sites of inflammation by galectin 3 [54]. Sim-
ilarly, other members of the galectin family have been
shown to stimulate production of pro-inflammatory
cytokines under intestinal inflammatory conditions
[55,56] suggesting an integral role of galectins in inflam-
matory host responses, with emphasis on the intestinal
induction site.
In general, the antibody response in chickens is similar to
mammals [57,58]. Avian IgY shares properties with both
mammalian IgG and IgE. Although in most cases, IgY
molecule is still referred to as chicken IgG, as it appears to
be functional equivalent to mammalian IgG. Despite lack-
ing evidence that birds produce the mammalian equiva-
lent of IgE, there is similarity in NE pathogenesis in
chickens compared to other IgE-mediated host responses
to gut-associated pathogens inducing intestinal inflam-
mation in mammals [59-61], suggesting that our observa-
tion on IgY R gene induction and previously reported IgY
antibody production following exposure to Cp proteins
may be representative of IgE activity. To validate the
hypothesis, further functional studies with chicken eosi-
nophils, antibody titres and hypersensitivity are required.
Lastly, TCR-γ expression was shown to be consistently up-
regulated in infected chickens, regardless of antibiotic
treatment, indicative of the involvement of γδ-T cells in
the host response to Cp infection. Specifically, γδ-T cells,
which are dominant at mucosal surfaces, have been
described to interact with innate immunity cells including
mammalian dendritic cells [62] and chicken NK-like cells
[63] during cellular activation, and presumably at the out-
set of pathogenic infection. In chickens, NK-like cell activ-
ity has been shown in intestinal epithelial lymphocyte
populations potentially containing chicken γδ-T cells
[64], and γδ-T cells have been reported within the caecum
[65]. Although further studies are required to determine
the role of this T cell sub-population in chickens during
Cp infection, our results suggest γδ-T cells may represent a
previously unreported innate immunity mechanism to
combat NE disease.
Conclusion
In conclusion, the data acquired from the present study
demonstrate the intricate and holistic magnitude of
chicken host response to Cp challenge and the develop-
ment of NE. Although the influence of dietary antibiotics
appeared to be less significant than the disease process,
both had a considerable impact on the host response.
Identification of target genes relevant to Cp infection and
antibiotic effect warrants further functional studies that
may lead to the determination of molecular mechanisms
underlying the chicken response and to the development
of effective control strategies for NE disease in poultry.
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